Abstract
The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan–Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909–3918.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink H, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-airlie house, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.
Melnyk A, Rodriguez A, Pugh WC, Cabannillas F . Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520.
Lopez-Guillermo A, Cid J, Salar A, Lopez A, Montalban C, Castrillo J et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 1998; 9: 849–855.
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d′études des lymphomes de l′adulte (GELA). Blood 1998; 92: 76–82.
Rudiger T, Weisenburger DD, Anderson JR, Armitage J, Diebold J, MacLennan K et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002; 13: 140–149.
Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider B, Greiner T et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913–3921.
Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697–2706.
Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta J, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775.
Vose JM, Peterson C, Bierman PJ, Weisenburger D, Linder J, Harrington D et al. Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 1990; 76: 424–431.
Song KW, Mollee P, Keating A, Crump M . Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985.
Ansell SM, Habermann TM, Kurtin PJ, Witzig T, Chen M, Li C et al. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296–2301.
Rodriguez J, Munsell M, Yazji S, Hagemeister F, Younes A, Andersson B et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657.
Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.
Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33: 405–410.
Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC . High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 2004; 33: 635–638.
Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M, Goldstone A . Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437–442.
Copelan E, Penza S, Pohlman B, Avalos B, Goormastic M, Andresen S et al. Autotransplantation following busulfan, etoposide, and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 25: 1243–1248.
Kurzrock R, Ravandi F . Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006; 43 (2 Suppl 2): S27–S34.
Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald A, Repp R et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924.
Talpur R, Apisarnthanarax N, Ward S, Duvic M . Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002; 43: 121–126.
Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R . Activity of interferon-α and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 2004; 100: 574–580.
Piekarz RL, Robey R, Sandor V, Bakke S, Wilson W, Dahmoush L et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865–2868.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Smith, S., Bolwell, B., Rybicki, L. et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 40, 239–243 (2007). https://doi.org/10.1038/sj.bmt.1705712
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705712
Keywords
This article is cited by
-
Advances in the pathogenesis and therapeutic strategies of angioimmunoblastic T-cell lymphoma
Clinical and Experimental Medicine (2023)
-
Accumulation, Chronicity, and Induction of Oxidative Stress Regulating Genes Through Allium cepa L. Functionalized Silver Nanoparticles in Freshwater Common Carp (Cyprinus carpio)
Biological Trace Element Research (2023)
-
How to Sequence Therapies in Peripheral T Cell Lymphoma
Current Treatment Options in Oncology (2021)
-
The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience
Annals of Hematology (2018)
-
High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis
International Journal of Hematology (2014)